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Abstract
Introduction MicroRNAs (miRNAs) are a class of small
noncoding RNAs that control gene expression by targeting
mRNAs and triggering either translation repression or RNA
degradation. Their aberrant expression may be involved in
human diseases, including cancer. To test the hypothesis that
there is a specific miRNA expression signature which
characterizes male breast cancers, we performed miRNA
microarray analysis in a series of male breast cancers and
compared them with cases of male gynecomastia and female
breast cancers.
Methods Paraffin blocks were obtained at the Department of
Pathology of Thomas Jefferson University from 28 male patients
including 23 breast cancers and five cases of male
gynecomastia, and from 10 female ductal breast carcinomas.
The RNA harvested was hybridized to miRNA microarrays
(~1,100 miRNA probes, including 326 human and 249 mouse
miRNA genes, spotted in duplicate). To further support the
microarray data, an immunohistochemical analysis for two
specific miRNA gene targets (HOXD10 and VEGF) was
performed in a small series of male breast carcinoma and
gynecomastia samples.

Introduction
Breast cancer is a rare disease in men, representing less than
1% of all malignancies and responsible for 0.1% of male cancer deaths [1,2]. Despite its infrequent prevalence, male
breast cancer can cause significant morbidity and mortality. In

Results We identified a male breast cancer miRNA signature
composed of a large portion of underexpressed miRNAs. In
particular, 17 miRNAs with increased expression and 26
miRNAs with decreased expression were identified in male
breast cancer compared with gynecomastia. Among these
miRNAs, some had well-characterized cancer development
association and some showed a deregulation in cancer
specimens similar to the one previously observed in the
published signatures of female breast cancer. Comparing male
with female breast cancer miRNA expression signatures, 17
significantly deregulated miRNAs were observed (four
overexpressed and 13 underexpressed in male breast cancers).
The HOXD10 and VEGF gene immunohistochemical
expression significantly follows the corresponding miRNA
deregulation.

Conclusions Our results suggest that specific miRNAs may be
directly involved in male breast cancer development and that
they may represent a novel diagnostic tool in the
characterization of specific cancer gene targets.

fact, it has a more aggressive clinical behavior compared with
female breast cancer [2]. Most of the current knowledge
regarding male breast cancer biology, natural history and treatment strategies is still limited and has been extrapolated from
its female counterpart.

HOXD10: homeobox-D10; IHC: immunohistochemical; miRNA: microRNA; PCR: polymerase chain reaction; VEGF: vascular endothelial growth factor.
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Genome-wide microarray gene expression analysis has been
largely used to characterize human cancers. This approach
allowed the identification of genes important in tumorigenesis.
Microarray tools have been recently enriched by the development of platforms for the analysis of microRNA (miRNA)
expression [3,4]. miRNAs are ~22-nucleotide small noncoding RNAs that modulate gene expression by binding to target
mRNA by imperfect complementary, causing either mRNA
degradation or translation inhibition [5]. In humans, aberrant
expression of miRNAs contributes to carcinogenesis by promoting the expression of proto-oncogenes or by inhibiting the
expression of tumor suppressor genes. Such oncomirs have
been demonstrated in a variety of hematologic and solid malignancies [6-8], and also in female breast cancer [9-31]. Furthermore, interfering with miRNA expression, an altered
experimental tumorigenesis has been observed [14,32].
Indeed, genome-wide profiling integrated by functional studies
that involve overexpression and downregulation of miRNAs
represents the current approach that is most likely to yield
advances in the new field of noncoding RNA research. Moreover, miRNAs are, in contrast to most mRNAs, long-lived in
vivo and very stable in vitro, which might be critical in a clinical
setting and may allow analysis of paraffin-embedded samples
[11].
Previous studies have demonstrated that there is a large
number of deregulated miRNAs in human breast cancer (in
particular, miR-10b, miR-17-5p, miR-21, miR-27a, miR-27b,
miR-125a, miR-125b, miR-126, miR-145, miR-155, miR200c, miR-206, miR-336 and the let-7 family) [9-31]. The
miRNA signatures have been correlated with clinicopathological and prognostic parameters such as tumor size, nodal
involvement, vascular invasiveness, ErbB2, estrogen receptor
status
and
chemotherapy
resistance
[9-11,13,2124,27,28,30,31]. Moreover, a functional polymorphism in the
miR-146a gene has been correlated with the predisposition to
an earlier age of onset of familial breast and ovarian cancers
[26]. Three recent studies proved the involvement of miRNAs
in breast cancer metastases [14,32,33]. For instance, miR10b overexpression leads to tumor invasion and metastasis by
suppressing HOXD10 and indirectly activating the prometastatic gene RHOC [14]. Two other miRNAs (miR-373 and
miR-520c) can also promote tumor invasion and metastasis, at
least in part by regulating the CD44 gene [32]. In addition,
miR-335, miR-206 and miR-126 have been identified as suppressors of breast cancer metastasis [33].
These findings strongly suggest that miRNA expression profiles could represent a promising new class of cancer biomarkers. Moreover, in the future, miRNAs could be potentially
used as innovative and targeted therapeutics [34].
In the present report we analyze the genome-wide miRNA
expression profile of 23 male breast carcinoma cases versus
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five male gynecomastia cases, and of 10 female breast carcinoma samples. Our data indicate a miRNA signature associated with male breast carcinoma and suggest miRNA
deregulation as an important event in male breast cell transformation.

Materials and methods
Tissue samples
After exempt status for the study was granted by the Institutional Review Board of Thomas Jefferson University, specimens from 28 male patients, including 23 cases of breast
cancer and five cases of gynecomastia, and from 10 female
patients affected by ductal breast carcinoma were identified
from the archival files of the Department of Pathology of Thomas Jefferson University (Philadelphia, PA, USA). The patients
had undergone treatment by either simple mastectomy or wide
local excision and radiotherapy. Adjuvant therapy was not
given. All cases were reviewed by two pathologists (JPP and
RB) and the diagnoses confirmed. Four 15 μm sections were
obtained from each case.

For the immunohistochemical study, formalin-fixed and paraffin-embedded tissues of 10 cases of male ductal breast carcinoma and five cases of gynecomastia were obtained from the
archival files of the Department of Surgical Pathology of the
University of Padova.
All patients considered in this study gave their written informed
consent. The male breast cancer samples have been considered in an earlier publication [35].
MicroRNA microarray
Tissue sections were deparaffinized with xylene at 50°C for 3
minutes. Total RNA extraction was undertaken using the
RecoverAll kit (Ambion Inc, Austin, TX, USA) according to the
manufacturer's instructions. RNA labeling and hybridization on
miRNA microarray chips were performed as previously
described [36]. Briefly, 5 μg total RNA from each sample were
reverse-transcribed using biotin end-labeled random-octamer
oligonucleotide primer. Hybridization of biotin-labeled complementary DNA was performed on a new Ohio State University
custom miRNA microarray chip (OSU_CCC version 4.0),
which contains ~1,100 miRNA probes – including 326 human
and 249 mouse miRNA genes, spotted in duplicate [3]. The
hybridized chips were washed and processed to detect biotincontaining transcripts by streptavidin- Alexa647 conjugate
and were scanned on an Axon 4000B microarray scanner
(Axon Instruments, Sunnyvale, CA, USA).
Statistical and bioinformatics analysis
Microarray images were analyzed using GENEPIX PRO 6.0
(Axon Instruments). Average values of the replicate spots of
each miRNA were background subtracted, normalized and further analyzed. Normalization was performed using quantiles
[3]. The microarray data have been deposited at the National
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Center for Biotechnology Information Gene Expression Omnibus repository [GEO:GSE17155].
miRNAs that are differentially expressed between breast cancer and gynecomastia were identified using a random-variance
t test. The random-variance t test is an improvement over the
standard separate t test as it permits sharing information
among genes about within-class variation without assuming
that all genes have the same variance [37]. Genes were considered statistically significant if their P value was less than
0.01. A stringent significance threshold was used to limit the
number of false positive findings [38]. Only mature miRNAs
that are differentially expressed are reported.
Our samples were not microdissected so, to further avoid the
influence of heterogeneity/a different percentage of cell types
between compared samples (cancer cells versus surrounding
stromal tissue cells), we performed an enrichment analysis for
the gynecomastia versus male breast cancer groups. The
enrichment analysis was performed by enriching the original
microarray analysis data for tumor area. For this purpose, the
tumor area – defined as the percentage of tumor over the stromal counterpart – was histologically determined by two pathologists (JPP and RB).
Quantitative real-time PCR
The single-tube TaqMan miRNA Assay (Applied Biosystems,
Foster City, CA, USA) was used to detect and quantify mature
miRNAs on Applied Biosystems real-time PCR instruments in
accordance with the manufacturer's instructions. Normalization was performed with the small nuclear RNA U48 (RNU48;
Applied Biosystems). All real-time reactions, including no-template controls and real-time minus controls, were run in a
GeneAmp PCR 9700 thermocycler (Applied Biosystems).
Gene expression levels were quantified using the ABI Prism
7900HT Sequence Detection System (Applied Biosystems).

Comparative real-time PCR was performed in triplicate, including no-template controls. The fold difference for each sample
was obtained using the expression 2-ΔCt, in which Ct is the
threshold cycle (the threshold cycle is the cycle number at
which the fluorescence generated within a reaction crosses
the threshold) and ΔCt is the difference between the average
Ct value of a sample gene and the average Ct for the endogenous reference RNU48. Total RNA from 19 of the 23 male
breast cancers and from the five gynecomastia samples were
used in the quantitative real-time PCR analysis. The RNA was
extracted from different tissue blocks to those used in the
miRNA microarray study.
Immunohistochemistry
Staining was performed automatically (Ventana Benchmark
XT system; Ventana Medical Systems, Touchstone, AZ, USA)
for vascular endothelial growth factor (VEGF) (catalog number
sc-152 – VEGF-A20, 1:100; Santa Cruz Biotechnology Inc.,

Santa Cruz, CA, USA) and homeobox-D10 (HOXD10) (catalog number sc-66926, 1:50; Santa Cruz Biotechnology Inc.)
according to the manufacturer's instructions. Sections were
then lightly counterstained with hematoxylin. Appropriate positive and negative controls were run concurrently. The expression of each immunohistochemical (IHC) marker was jointly
scored by two pathologists (MF and MR). Cytoplasmic positivity was considered for VEGF, and both cytoplasmic and membranous positivity were considered for HOXD10. Regarding
the IHC score intensity, positive staining was semi-quantified
with a three-tier system: negative positivity, low-grade positivity, high-grade positivity. Results were reported as positive
when staining was observed in at least 5% of the tumor cells.
When the staining intensity was heterogeneous, the highest
result was retained for scoring.

Results
MicroRNA expression signatures discriminate between
gynecomastia and cancer and between male and female
breast cancers
To identify deregulated miRNAs in male breast cancers, the
miRNA expression profiles were determined for five male
gynecomastia samples, 23 male breast cancer samples and
10 female breast cancer samples using a custom microarray
platform proven to give robust results, as validated by several
studies [3,4,10,12]. All of the 23 male breast cancer samples
pathologically corresponded to invasive ductal breast carcinoma. The clinicopathological characteristics are summarized
in Table 1.

Comparison analysis showed the differential expression of
several miRNA genes between gynecomastia and male breast
cancer. In detail, we identified 17 miRNAs with increased
expression and 26 miRNAs with decreased expression in male
breast cancer samples in comparison with gynecomastia samples (Table 2).
Although our samples were partially microdissected, contamination by surrounding stromal cells was unavoidable. We
therefore performed an enriched analysis for the tumor area
(Table 3). miR-499-3p and miR-330-5p miRNA follow the
enrichment, decreasing in the gynecomastia and increasing in
the male breast cancer samples.
No significant association has been observed between clinicopathological tumor characteristics and miRNA gene
expression.
In the search for male/female breast cancer specific miRNAs,
we correlated male breast cancer with female breast cancer
miRNA gene expression profiles. This sex-specific comparison
showed a different expression of 17 miRNAs between the two
categories, with four upregulated and 13 downregulated miRNAs in male breast cancers (Table 4 and Figure 1).
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Table 1
Clinicopathological characteristics of the 23 male breast cancer samples
Characteristic

Value

Age

71.2 ± 9.0 (72.0)

Tumor size

20.0 ± 9.6 (20.0)

Diagnosis
Invasive ductal carcinoma

11 (47.8%)

Invasive ductal carcinoma + ductal carcinoma in situ

12 (52.2%)

Nuclear grade
I

3 (13.0%)

II

11 (47.8%)

III

9 (39.1%)

Histological grade
I

2 (8.7%)

II

12 (52.2%)

III

9 (39.1%)

Cytokeratin 5/6
0

19 (82.6%)

+

1 (4.3%)

++

3 (13.0%)

+++

0 (0.0%)

Cytokeratin 14
0

19 (82.6%)

+

2 (8.7%)

++

0 (0.0%)

+++

2 (8.7%)

Cytokeratin 18
0

1 (4.3%)

+

0 (0.0%)

++

3 (13.0%)

+++

19 (82.6%)

1

13 (56.5%)

2

10 (43.5%)

pT

pN
0

8 (34.8%)

1

8 (34.8%)

2

1 (4.3%)

x

6 (26.1%)

pM
0

8 (34.8%)

1

2 (8.7%)

x

13 (56.5%)

Estrogen receptors
Positive

12 (95.7%)

Negative

1 (4.3%)

Not available

10

Progesterone receptors
Positive

13 (100.0%)

Negative

0 (0.0%)

Not available

10

Data presented as the mean ± standard deviation (median) or as n (%). -, negative; +, < 25%; ++, 25 to 50%; and +++, > 50%.
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Table 2
MicroRNA differential expression between male breast cancers and cases of male gynecomastia
MicroRNA

Cancer normalized

Gynecomastia normalized

Fold changea

P value

hsa-miR-26a-2

82.5

15.4

5.357

0.002517

hsa-miR-26b

137.7

27.2

5.062

0.006413

hsa-miR-499-3p

290.6

63.9

4.548

0.005332

hsa-miR-607

389.4

87

4.476

0.001533

hsa-miR-135b

199.3

45.7

4.361

0.008074

hsa-miR-616

269.9

66

4.089

0.008253

hsa-miR-769-5p

184.4

53.6

3.44

0.006534

hsa-miR-330-5p

291.1

89.2

3.263

0.001353

hsa-miR-132

155.7

49.2

3.165

0.007551

hsa-miR-149

461.7

161.6

2.857

0.003765

hsa-miR-557

686.1

286.4

2.396

0.005408

hsa-miR-29b-2

1,273.7

604.9

2.106

1.12 × 10-5

hsa-miR-657

2,499.3

1,277.2

1.957

0.000899

hsa-miR-483-3p

18,985.9

10,525.1

1.804

0.001411

hsa-miR-371-3p

9,741.4

5,642.1

1.727

0.003106

hsa-miR-593

1,805.1

1,051.3

1.717

0.001461

hsa-miR-596

1,430.8

909.5

1.573

0.000370

hsa-miR-92a

6,490.7

11,614.8

- 1.789

0.008752

hsa-miR-145

1,561.5

3,649.3

- 2.336

0.000110

hsa-miR-99b

678.8

1,697.8

- 2.500

0.000985

hsa-miR-214

1,392.7

3,717.6

- 2.667

4.31 × 10-5

hsa-miR-191

1,337.8

4,112

- 3.077

0.003671

hsa-miR-454

11.2

36.2

- 3.236

0.006250

hsa-miR-10a

1,765.9

5,748.8

- 3.257

5 × 10-6

hsa-miR-195

188.2

865.9

- 4.608

0.008269

hsa-miR-10b

13.4

84.9

- 6.329

0.000451

hsa-miR-130a

451.8

2,868.5

- 6.329

0.003837

hsa-miR-374a

18.1

128.8

- 7.092

0.000556

hsa-miR-146b-5p

190.4

1,459.9

- 7.692

0.005392

hsa-miR-146a

129.2

1,070.7

- 8.264

0.007859

hsa-miR-181c

63.9

539.1

- 8.403

0.001424

hsa-miR-218

10

99.7

- 10.000

3 × 10-7

hsa-let-7g

59

611.5

- 10.417

0.002014

hsa-miR-15b

21.5

229.2

- 10.638

0.001555

hsa-miR-125a-5p

62.5

790.1

- 12.658

0.001136

hsa-miR-223

79.8

1,158.8

- 14.493

0.000837

hsa-miR-99a

70

1,111.4

- 15.873

0.000261

hsa-miR-140-3p

18.1

291.8

- 16.129

2.31 × 10-5

hsa-miR-126

16.7

2,71.9

- 16.393

5.67 × 10-5

hsa-miR-199b-3p

136

2,517.8

- 18.519

0.003903

hsa-miR-100

84.9

1,757.3

- 20.833

0.000104

hsa-miR-199a-5p

35.3

782.6

- 22.222

0.000256

hsa-miR-125b

95.3

2,992.6

- 31.250

9.91 × 10-5

aPresented

as the actual change in expression.
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Table 3
MicroRNA differential expression between male breast cancers and male gynecomastia after enrichment for tumor cellularity
MicroRNA

Cancer normalized

Gynecomastia normalized

Fold changea

P value

hsa-miR-499-3p

300.2

17.7

16.96

0.000361

hsa-miR-129-3p

124.3

10.0

12.43

0.001482

hsa-miR-330-5p

322.1

66.6

4.836

0.003715

hsa-miR-10a

1829.8

6683.6

- 3.650

0.000353

hsa-miR-191

1655.3

6552.6

- 3.952

0.007160

hsa-miR-338-5p

17.3

106.7

- 6.173

0.005437

hsa-miR-218

10.0

74.6

- 7.463

0.000527

hsa-miR-369-3p

17.5

151.8

- 8.674

0.002524

hsa-miR-454

11.8

102.8

- 8.711

0.000753

hsa-miR-10b

15.1

132.8

- 8.772

0.005204

hsa-miR-374a

17.6

238.3

- 13.514

0.000447

hsa-miR-126

18.8

315.2

- 16.667

0.003277

hsa-miR-140-3p

18.6

340.7

- 18.182

0.000843

aPresented

as the actual change in expression.

Quantitative real-time PCR analysis
To confirm the results of microarray analysis, we performed
quantitative real-time PCR analysis on a limited number of
samples (19 cancer samples, five gynecomastia samples)
using probes corresponding to miR-125b, miR-126, miR-10b,
miR-10a, miR-191, miR-26b, miR-607 and miR-135b (Figure
2). The quantitative real-time PCR analysis confirmed the
results obtained by microarray analysis. In fact, miR-125b,
miR-126, miR-10b, miR-10a and miR-191 were underexpressed whereas miR-26b, miR-607 and miR-135b were
overexpressed in cancer samples examined, in comparison
with the gynecomastia samples.

Immunohistochemical analysis
To further confirm our microarray data, and to demonstrate
that miRNA analysis may be important in investigations into
male breast cancer specific genes, we sought to correlate the
expression of significantly deregulated miRNA genes in male
breast cancer samples with two of their previously reported
targets (Figure 3a). For this purpose, we performed an IHC
analysis on the HOXD10 and VEGF genes [14,39].

The HOXD10 gene represses the expression of genes
involved in cell migration and extracellular matrix remodeling in
breast cancer cells, and it is regulated by miR-10b [14]. Since
we observed miR-10b to be downregulated in male breast
cancers, we therefore decided to analyze HOXD10 expression in formalin-fixed paraffin-embedded tissue samples

Figure 1

MicroRNA differential expression in male versus female breast cancers.
cancers Hierarchical clustering of the 17 microRNA genes with a significantly different expression. Rows, individual genes; columns, individual tissue samples. Pseudocolors indicate transcript levels below, equal to, or above the
mean (green, black, and red, respectively). The scale represents the intensity of gene expression (log2 scale ranges between -3 and 3).
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Table 4
MicroRNA differential expression between male and female breast cancers
MicroRNA

Male normalized

Female normalized

Fold changea

P value

hsa-miR-663

492.9

77.5

6.369

7.1 × 10-6

hsa-miR-618

428.3

106.7

4.444

2.0 × 10-7

hsa-miR-605

174.0

44.4

3.922

0.000373

hsa-miR-616

309.2

86.0

3.597

0.000213

hsa-miR-200b

147.6

642.8

- 4.354

0.000144

hsa-miR-181c

145.9

656.1

- 4.500

0.000624

hsa-miR-106a

199.3

914.7

- 4.589

0.000594

hsa-miR-125a-5p

131.0

697.9

- 5.326

0.000698

hsa-miR-16

351.6

2021.7

- 5.750

0.000871

hsa-miR-25

309.3

1875.1

- 6.062

0.000992

hsa-miR-100

196.8

1206.9

- 6.132

0.000160

has-let-7f

39.0

241.4

- 6.186

0.000380

hsa-miR-125b

206.6

1427.7

- 6.912

0.000513

hsa-miR-15b

48.7

364.5

- 7.108

0.000508

hsa-miR-425

53.5

436.3

- 8.161

0.000614

hsa-miR-199a-5p

84.7

710.0

- 8.387

0.000306

hsa-miR-223

167.3

1414.6

- 8.454

0.000111

aPresented

as the actual change in expression.

Figure 2

obtained from 10 male breast cancer patients and five gynecomastia patients. As expected, the five gynecomastia samples showed a weak cytoplasmic HOXD10 IHC positivity,
whereas 8/10 male breast cancers samples showed
HOXD10 moderate- strong cytoplasmic positivity with membranous reinforcement (Figure 3b to 3d).
VEGF is a positive regulator of angiogenesis, and its expression is upregulated in many types of cancers, including breast
cancers. VEGF is also a target protein of miR-126 [39]. Given
the downregulation of miR-126 in male breast cancers, we
tested VEGF IHC expression in our series of male breast cancers/gynecomastia. In gynecomastia samples VEGF showed
weak cytoplasmic immunoreactions, whereas in 9/10 males a
strong cytoplasmic reactivity was observed (Figure 3e to 3g).

Discussion
Quantitative
male
breast cancers
real-time PCR validation of microRNA microarray results in
male breast cancers. Relative expression of microRNAs in male breast
cancer compared with cases of gynecomastia by real-time PCR. miR125b, miR-126, miR-10b, miR-10a and miR-191 were underexpressed
in cancer samples, whereas miR-26b, miR-607 and miR-135b were
overexpressed. Dots, normalized ratio microRNA gene expression values (breast cancers/gynecomastia); error bars, standard deviation.

Aberrant miRNA expression patterns have been described in
a variety of hematologic and solid-organ malignancies, and
several miRNA signatures have also been described for female
breast cancer [10-30]. In the present study we have identified
a global expression pattern of miRNAs that can differentiate
gynecomastia from male breast cancer and can differentiate
male breast cancer from female cancers.
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Figure 3

miR-10b and miR126 genes are downregulated in male breast cancers versus gynecomastia
gynecomastia. (a) Columns represent individual tissue samples.
Pseudocolors indicate transcript levels below, equal to, or above the mean (green, black, and red, respectively). The scale represents the intensity of
gene expression (log2 scale ranges between -3 and 3). Representative examples of (b), (c), (d) homeobox-D10 and (e), (f), (g) vascular endothelial
growth factor immunohistochemical expression in male breast cancers and gynecomastia samples. (b) and (e) Weak immunohistochemical staining
in gynecomastia samples. (c), (d), (f) and (g) Positive immunoreactions in male breast cancer samples.

Gynecomastia is the most common clinical and pathologic
abnormality of the male breast. It results from hypertrophy of
breast tissue. Numerous conditions have been associated
with gynecomastia, but the pathophysiological bases are due
to an imbalance of sex hormones and the tissue responsiveness to them.
Previous studies of miRNA expression in human breast cancer
have focused on comparing normal tissues with tumor samples [10,11,21]. Because of the absence in men of a normal
nonhypertrophic breast gland, we choose to compare gynecomastia with male breast cancer. In fact, gynecomastia has a
higher amount of breast epithelium than normal breast. Gynecomastia could therefore be considered a good normal control
for male breast cancer.
We identified a miRNA signature for male breast cancer, composed of 43 miRNAs that were differently expressed between
tumors and gynecomastia samples. In particular, 17 miRNAs
were upregulated and 26 miRNAs were downregulated in
cancers (Table 2). Interestingly, in this signature we identified
miRNAs that had previously been associated with breast cancers compared with normal tissues. Two overexpressed miRNAs – miR-149 [10] and miR-29b [12,21,22] – have already
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been described as upregulated in other female breast cancer
studies. On the other hand, miR-145 [10,20], miR-10b [10],
let-7g [19], miR-125a-5p [10,31], miR-125b [31] and miR126 [40] have been described as downregulated.
According to previous reports in female breast carcinogenesis, the most interesting and promising miRNAs of this male
breast cancer signature are miR-10b, miR-126, miR-125a-5p
and miR-125b [14,31,40].
miR-10b has been previously described as downregulated in
female breast cancer compared with normal tissue [10], but it
has been also associated with the induction of tumor invasion
and metastasis of breast cancer derived cells by targeting
HOXD10 [14]. The downregulation of HOXD10 permits subsequently the expression of the prometastatic gene product
RHOC, favoring, in turn, cancer cell migration and invasion
[14]. Gee and colleagues, however, showed that miR-10b is
not significantly associated with breast cancer metastasis in a
large series of early-stage breast cancers [41].
We observed in our tumor samples a downregulation of miR125a-5p, miR-125b, miR-126, miR-145 and let-7g genes,
which have been shown to be related to hormonal settings and

Available online http://breast-cancer-research.com/content/11/4/R58

ErbB2 status of the tumor: miR-125a-5p and miR-125b downregulate ErbB2 and ErbB3 expression [31], miR-126 and let7g are upregulated in ErbB2-negative tumors, whereas miR145 is upregulated in ErbB2-negative tumors and upregulated
in estrogen-receptor-positive and progesterone-receptor-positive tumors [13].

The functional significance of miRNA dysregulation we have
shown needs to be further investigated. Our results suggest
that specific miRNAs may be directly involved in male breast
cancer development and that they may represent a novel diagnostic tool in the characterization of specific cancer gene targets.

Our IHC study supports previous reports on the relationship of
miR-10b and miR-126 and their respective gene targets
[14,39]. Larger prospective studies are needed to confirm our
IHC data, but we have further suggested that miRNA profiling
may be helpful in the discovery of new breast cancer gene targets.
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